

Please type a plus sign (+) inside this box → ☐

PTO/SB/05 (2/98)

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**UTILITY  
PATENT APPLICATION  
TRANSMITTAL**

(Fee for new nonprovisional applications under 37 CFR 1.53(b))

Attorney Docket No.	38-21(15749)B
First Named Inventor or Application Identifier	FISHER
Title	Nucleic Acid Sequences from <i>Cyanidium caldarium</i> and Uses Thereof
Express Mail Label No.	

**APPLICATION ELEMENTS**

MPEP chapter 600 concerning utility patent application contents

**ADDRESS TO:** Assistant Commissioner for Patents  
Box Patent Application  
Washington, DC 20231

1. ☒ \*Fee Transmittal Form (Form PTO-1082)  
(Submit an original and a duplicate for fee processing)
2. ☒ Specification [Total Pages 113]  
(preferred arrangement set forth below)
- Descriptive title of the Invention
  - Cross References to Related Applications
  - Statement Regarding Fed sponsored R&D
  - Reference to Microfiche Appendix
  - Background of the Invention
  - Brief Summary of the Invention
  - Brief Description of the Drawings (if filed)
  - Detailed Description
  - Claims
  - Abstract of the Disclosure
- ☐ Drawing(s) (35 USC 113) [Total Sheets ]
- Oath or Declaration [Total Pages 6]
- a. ☒ Newly executed (original or copy)
- b. ☐ Copy from a prior application (37 CFR 1.63(d))  
(for continuation/divisional with Box 17 completed)  
[Note Box 5 below]
- i. ☐ **DELETION OF INVENTOR(S)**  
Signed statement attached deleting inventor(s) named  
in the prior application, see 37 CFR 1.63(d)(2) and  
1.33(b).
5. ☐ Incorporation By Reference (useable if Box 4b is checked)  
The entire disclosure of the prior application, from which a copy  
of the oath or declaration is supplied under Box 4b, is considered  
as being part of the disclosure of the accompanying application  
and is hereby incorporated by reference therein.

6. ☐ Microfiche Computer Program (Appendix)
7. Nucleotide and/or Amino Acid Sequence Submission  
(if applicable, all necessary)
- a. ☒ Computer Readable Copy
- b. ☒ Paper Copy (identical to computer copy)
- c. ☒ Statement verifying identity of above copies

**ACCOMPANYING APPLICATION PARTS**

8. ☐ Assignment Papers (cover sheet & document(s))
9. ☐ 37 CFR 3.73(b) Statement (when there is an assignee) ☐ Power of Attorney
10. ☐ English Translation Document (if applicable)
11. ☒ Information Disclosure Statement (IDS)/PTO-1449 ☒ Copies of IDS Citations
12. ☐ Preliminary Amendment
13. ☒ Return Receipt Postcard (MPEP 503) (Two)  
(should be specifically itemized)
14. ☐ \*Small Entity Statement(s) ☐ Statement filed in prior application, Status still proper and desired
15. ☐ Certified Copy of Priority Document(s)  
(if foreign priority is claimed)
16. ☐ Other:

\*NOTE FOR ITEMS 1 & 14: IN ORDER TO BE ENTITLED TO PAY SMALL ENTITY FEES, A SMALL ENTITY STATEMENT IS REQUIRED (37 C.F.R. § 1.27), EXCEPT IF ONE FILED IN A PRIOR APPLICATION IS RELIED UPON (37 C.F.R. § 1.28).

**17. If a CONTINUING APPLICATION, check appropriate box and supply the requisite information:**

☐ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application No: /

Prior Application Information: Examiner: Group/Art Unit:

**18. CORRESPONDENCE ADDRESS**

☐ Customer Number or Bar Code Label or ☒ Correspondence address below  
(Insert Customer No. or Attach bar code label here)

NAME	Lawrence M. Lavin, Jr., Esq.				
	Monsanto/GD Searle				
ADDRESS	Patent Department Central				
	PO Box 5110				
CITY	Chicago	STATE	Illinois	ZIP CODE	60680-5110
COUNTRY	US	TELEPHONE	(314) 694-3602	FAX	(314) 694-1671
Name (Print/Type)	Lawrence M. Lavin, Jr.	Registration No. (Attorney/Agent)	30,768		
Signature	Lawrence M. Lavin, Jr.	Date	April 3, 2000		

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.

41,408

April 3, 2000

**Box Patent Application**

Assistant Commissioner for Patents  
Washington, D.C. 20231

Re: U.S. Non-Provisional Utility Patent Application  
Application No.: To Be Assigned  
Filed: Herewith  
For: **Nucleic Acid Sequences from *Cyanidium caldarium* and Uses Thereof**  
Inventors: Dane K. FISHER *et al.*  
Atty. Docket: 38-21(15749)B

Sir:

The following documents are forwarded herewith for appropriate action by the U.S. Patent and Trademark Office:

1. Utility Patent Application Transmittal (PTO/SB/05);
2. Form PTO-1082 (in duplicate);
3. U.S. Utility Patent Application entitled:

**Nucleic Acid Sequences from *Cyanidium caldarium* and Uses Thereof**

and naming as inventors:

**Dane K. FISHER and Raghunath V. LALGUDI,**

the application consisting of:


- a. A specification containing:
  - (i) 111 pages of a description prior to the claims;
  - (ii) 1 pages of claims (7 claims);
  - (iii) a one (1) page abstract; and
  - (iv) 2,451 pages of a sequence listing;

4. Statement Regarding Sequence Submission;
5. A CD-ROM containing the sequence listing;
6. Original Declaration and Power of Attorney, executed by inventor Dane K. Fisher (3 pages);
7. Original Declaration and Power of Attorney, executed by inventor Raghunath V. Lalgudi (3 pages);
8. An Information Disclosure Statement;
9. Form PTO-1449 (1 page), with 8 accompanying documents; and
10. Two (2) return postcards.

It is respectfully requested that, of the two attached postcards, one be stamped with the filing date of these documents and returned to our courier, and the other, prepaid postcard, be stamped with the filing date and unofficial application number and returned as soon as possible.

In accordance with 37 C.F.R. § 1.821(f), the paper copy of the sequence listing and the computer readable copy of the sequence listing submitted herewith in the above application are the same.

Respectfully submitted,



David R. Marsh (Reg. No. 41,408)

Enclosures

**MONSANTO/GD SEARLE**  
**Patent Department Central**  
**P.O. Box 5110**  
**Chicago, Illinois 60680-5110**  
**(314) 694-3602**

Attorney Docket No. 38-21(15749)B

ASSISTANT COMMISSIONER FOR PATENTS  
 Washington, DC 20231

Sir:

Transmitted herewith for filing is the patent application of

Inventors: Dane K. FISHER et al.For: Nucleic Acid Sequences from *Cyanidium caldarium* and Uses Thereof

Enclosed are:

- ☐ \_\_\_\_\_ sheets of informal drawings.  
☐ An assignment of the invention to \_\_\_\_\_  
☐ Form PTO-1595.  
☐ A certified copy of a \_\_\_\_\_ application.  
☐ A verified statement to establish small entity status under 37 C.F.R. § 1.9 and 37 C.F.R. § 1.27.  
☒ Executed Combined Declaration and Power of Attorney for Patent Application (6 total pages).

The filing fee has been calculated as shown below:

	(Col. 1)	(Col. 2)
FOR	NO. FILED	NO. EXTRA
BASIC FEE		
TOTAL CLAIMS	7 - 20 =	* 0
INDEP. CLAIMS	3 - 3 =	* 0
<input type="checkbox"/> MULTIPLE DEPENDENT CLAIM PRESENTED		

\*If the difference in Col. 1 is less than zero, enter "0" in Col. 2

SMALL ENTITY	
RATE	FEE
	345.00
x 9 =	
x 39 =	
+ 130 =	
TOTAL	\$

OTHER THAN A SMALL ENTITY	
RATE	FEE
	690.00
x 18 =	0.00
x 78 =	0.00
+ 260 =	
TOTAL	\$ 690.00

☒ Please charge my Deposit Account No. 13-4125 in the amount of \$690.00. A duplicate copy of this sheet is attached.

☐ Check No. \_\_\_\_\_ in the amount of \$ \_\_\_\_\_ to cover the filing fee is enclosed.

☒ The U.S. Patent and Trademark Office is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. 13-4125 referencing docket number 38-21(15746)B.  
 A duplicate copy of this sheet is attached.

☒ Any additional filing fees required under 37 C.F.R. § 1.16.

☒ Any patent application processing fees under 37 C.F.R. § 1.17.

☐ The U.S. Patent and Trademark Office is hereby authorized to charge payment of the following fees during the pendency of this application or credit any overpayment to Deposit Account No. 13-4125 referencing docket number \_\_\_\_\_.  
 A duplicate copy of this sheet is attached.

☐ Any patent application processing fees under 37 C.F.R. § 1.17.

☐ The issue fee set in 37 C.F.R. § 1.18 at or before mailing of the Notice of Allowance, pursuant to 37 C.F.R. § 1.311(b).

☐ Any filing fees under 37 C.F.R. § 1.16 for presentation of extra claims.

Date: April 3, 2000

Lawrence M. Lavin Jr.  
 Lawrence M. Lavin, Jr. (Reg. No. 30,768)

by R. Mafl 41, 408